top of page

We are committed to collaborating with leaders in the immuno-oncology field to realize the full potential of our T-SIGn® platform.

!
Widget Didn’t Load
Check your internet and refresh this page.
If that doesn’t work, contact us.
!
Widget Didn’t Load
Check your internet and refresh this page.
If that doesn’t work, contact us.

In addition to our internal pipeline development efforts, Akamis Bio is committed to collaborating with leaders in the immuno-oncology field from academia, research institutes, and the biopharma industry to realize the full potential of our tumor gene therapy platform. We have a number of ongoing collaborations which are focused on both novel T-SIGn® therapeutic development, as well as on the use of our existing pipeline programs in combination with other immuno-oncology modalities.

 

Akamis Bio is always seeking to identify potential partners with complementary technology to our T-SIGn® platform. In particular, we are interested in collaborating with companies working on immuno-oncology modalities with strong potential to synergize with our T-SIGn® therapeutics to deliver enhanced efficacy in the solid tumor setting (e.g., checkpoint inhibitors, antibody drug conjugates, bispecific T-cell engagers, and cell therapies).
 

Interested in collaborating with Akamis Bio?

 

Please visit our Contact Us page to start a dialog.

bottom of page